Edinburgh-based NuCana BioMed Ltd has raised $57 million in a Series B financing round to support the development of cancer medicines that are chemically adapted nucleoside analogues, reportedly with an enhanced ability to trigger cancer cell death. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
